Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.

Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism.

Contraception (1997-05-01)

F Z Stanczyk

PMID9220223

ZUSAMMENFASSUNG

The purpose of the present report is to summarize the most important pharmacokinetic features of the new progestogens. In addition, the question of whether or not gestodene, in comparison to desogestrel, has an influence on the pharmacokinetics of ethinylestradiol (EE2) will be addressed.

MATERIALIEN

Produktnummer

Marke

Produktbeschreibung

E4876

Sigma-Aldrich

17α-Ethinylestradiol, ≥98%

PHR1480

Supelco

Ethinylestradiol, Pharmaceutical Secondary Standard; Certified Reference Material

1260001

USP

Ethinylestradiol, United States Pharmacopeia (USP) Reference Standard

E1900000

Ethinylestradiol, European Pharmacopoeia (EP) Reference Standard

E-076

Supelco

17α-Ethynylestradiol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

SML0292

Sigma-Aldrich

Gestoden, ≥98% (HPLC)

Y0001124

Ethinylestradiol für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

Y0000509

Desogestrel for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001112

Gestoden, European Pharmacopoeia (EP) Reference Standard

Y0000510

Desogestrel für die Systemeignung, European Pharmacopoeia (EP) Reference Standard